Disease monitoring of hepatocellular carcinoma through metabolomics

World Journal of Hepatology

Volumn 9, Issue 1, 2017, Pages 1-17

  Fitian, Asem I ^a   Cabrera, Roniel ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarkers; Chromatography mass spectrometry; Cirrhosis; Hepatocellular carcinoma; Metabolic profiling; Metabolomics; Noninvasive biomarkers

Indexed keywords

EID: 85009247838     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v9.i1.1     Document Type: Article

References (77)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491 [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753]
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
3. Hussain SM, Semelka RC, Mitchell DG. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am 2002; 10: 31-52, v [PMID: 11998574 DOI: 10.1016/S1064-9689 (03)00048-5]
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007. 04.061]
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
6. Kew MC. Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol 2013; 12: 173-182 [PMID: 23396727]
7. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, Valle D, Sperandeo M, Rapaccini GL, Gasbarrini G. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology 2000; 47: 1654-1658 [PMID: 11149026]
8. Gupta S, Bent S, Kohlwes J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50 [PMID: 12834318 DOI: 10.7326/0003-4819-139-1-200307010-00012]
9. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008; 2: 17-30 [PMID: 19669276 DOI: 10.1007/s12072-007-9038-x]
10. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005; 7: 26-34 [PMID: 18333158 DOI: 10.1080/13651820410024049]
11. Chen CH, Lin ST, Kuo CL, Nien CK. Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 1423-1427 [PMID: 18795704]
12. Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol 2012; 2012: 893103 [PMID: 22792474 DOI: 10.1155/2012/893103]
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
14. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18: 990-997 [PMID: 8406374 DOI: 10.1002/hep. 1840180434]
15. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000; 462: 381-393 [PMID: 10767647 DOI: 10.1016/S1383-5742(00)00027-2]
16. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol 2011; 4: 5-10 [PMID: 21317990 DOI: 10.1177/1756283X10385964]
17. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 Suppl 4: 5-13 [PMID: 21115576 DOI: 10.1634/theoncologist.2010-S4-05]
18. Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q, Ye Q. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med 2012; 29: 832-840 [PMID: 22344546]
19. Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One 2013; 8: e59459 [PMID: 23527199 DOI: 10.1371/journal.pone.0059459]
20. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. Des-gamma-carboxy prothrombin and alphafetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502 [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031]
21. Woo HG, Park ES, Thorgeirsson SS, Kim YJ. Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog 2011; 50: 235-243 [PMID: 21465573 DOI: 10.1002/mc.20691]
22. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55: 483-490 [PMID: 21953299 DOI: 10.1002/hep.24703]
23. Rodrigues RR, Barry CT. Gene pathway analysis of hepatocellular carcinoma genomic expression datasets. J Surg Res 2011; 170: e85-e92 [PMID: 21601879 DOI: 10.1016/j.jss.2011.04.004]
24. Pleguezuelo M, Lopez-Sanchez LM, Rodriguez-Ariza A, Montero JL, Briceno J, Ciria R, Muntane J, de la Mata M. Proteomic analysis for developing new biomarkers of hepatocellular carcinoma. World J Hepatol 2010; 2: 127-135 [PMID: 21160983]
25. Nguyen P, Leray V, Diez M, Serisier S, Le Bloc'h J, Siliart B, Dumon H. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 2008; 92: 272-283 [PMID: 18477307 DOI: 10.1111/j.1439-0396.2007.00752.x]
26. Mitra V, Metcalf J. Metabolic functions of the liver. Anaes Inten Care Med 2009; 10: 334-335 [DOI: 10.1016/j.mpaic.2009.03.011]
27. Xu EY, Schaefer WH, Xu Q. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Curr Opin Drug Discov Devel 2009; 12: 40-52 [PMID: 19152212]
28. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res 2007; 6: 2605-2614 [PMID: 17564425 DOI: 10.1021/pr070063h]
29. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011; 71: 6590-6600 [PMID: 21900402 DOI: 10.1158/0008-5472.CAN-11-0885]
30. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011; 10: M110.004945 [PMID: 21518826]
31. Wu FX, Wang Q, Zhang ZM, Huang S, Yuan WP, Liu JY, Ban KC, Zhao YN. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionizationtime-of-flight mass spectroscopy. Cancer Lett 2009; 279: 163-170 [PMID: 19268439 DOI: 10.1016/j.canlet.2009.01.034]
32. Cao H, Huang H, Xu W, Chen D, Yu J, Li J, Li L. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 2011; 691: 68-75 [PMID: 21458633 DOI: 10.1016/j.aca.2011.02.038]
33. Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci 2009; 100: 782-785 [PMID: 19469021 DOI: 10.1111/j.1349-7006.2009.01086.x]
34. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009; 648: 98-104 [PMID: 19616694 DOI: 10.1016/j.aca.2009.06.033]
35. Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, Ikeda S, Hirayama A, Yamamoto T, Yoshida H, Otsuka M, Tsuji S, Yatomi Y, Sakuragawa T, Watanabe H, Nihei K, Saito T, Kawata S, Suzuki H, Tomita M, Suematsu M. Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 2011; 55: 896-905 [PMID: 21334394 DOI: 10.1016/j.jhep.2011.01.031]
36. Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR, Zhao Y, Wang J, Di Poto C, Cheema AK, Tadesse MG, Goldman R, Shetty K. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 2012; 743: 90-100 [PMID: 22882828 DOI: 10.1016/j.aca.2012.07.013]
37. Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, Di Poto C, Wang J, Goerlitz D, Luo Y, Cheema AK, Sarhan N, Soliman H, Tadesse MG, Ziada DH, Ressom HW. LCMS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res 2012; 11: 5914-5923 [PMID: 23078175 DOI: 10.1021/pr300673x]
38. Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, Chen Y, Xu J, Zheng S, Li L. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 2012; 11: 1217-1227 [PMID: 22200553 DOI: 10.1021/pr2009252]
39. Zhou L, Ding L, Yin P, Lu X, Wang X, Niu J, Gao P, Xu G. Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatographymass spectrometry. J Proteome Res 2012; 11: 5433-5442 [PMID: 22946841 DOI: 10.1021/pr300683a]
40. Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Ziol M, Seror O, Dhonneur G, Trinchet JC, Beaugrand M, Le Moyec L. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin Cancer Res 2012; 18: 6714-6722 [PMID: 23136190 DOI: 10.1158/1078-0432.CCR-12-1099]
41. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, Lu X, Yang S, Gu J, Xu G. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009; 5: 868-876 [PMID: 19603122 DOI: 10.1039/b820224a]
42. Li S, Liu H, Jin Y, Lin S, Cai Z, Jiang Y. Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2369-2375 [PMID: 21763219 DOI: 10.1016/j.jchromb.2011.06.018]
43. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, Qin LX, Ye QH, Jia HL, Fan J, Sun HC, Tang ZY, Wang XW. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 2013; 144: 1066-1075.e1 [PMID: 23376425 DOI: 10.1053/j.gastro.2013.01.054]
44. Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013; 58: 229-238 [PMID: 23463346 DOI: 10.1002/hep.26350]
45. Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int 2014; 34: 1428-1444 [PMID: 24661807 DOI: 10.1111/liv.12541]
46. Gao R, Cheng J, Fan C, Shi X, Cao Y, Sun B, Ding H, Hu C, Dong F, Yan X. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma. Sci Rep 2015; 5: 18175 [PMID: 26658617 DOI: 10.1038/srep18175]
47. Meyer K, Jia Y, Cao WQ, Kashireddy P, Rao MS. Expression of peroxisome proliferator-activated receptor alpha, and PPARalpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice. Int J Oncol 2002; 21: 1175-1180 [PMID: 12429965]
48. Lalwani ND, Reddy MK, Qureshi SA, Reddy JK. Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis 1981; 2: 645-650 [PMID: 7273344 DOI: 10.1093/carcin/2.7.645]
49. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001; 21: 193-230 [PMID: 11375435 DOI: 10.1146/annurev.nutr.21.1.193]
50. Christensen E, Woldseth B, Hagve TA, Poll-The BT, Wanders RJ, Sprecher H, Stokke O, Christophersen BO. Peroxisomal betaoxidation of polyunsaturated long chain fatty acids in human fibroblasts. The polyunsaturated and the saturated long chain fatty acids are retroconverted by the same acyl-CoA oxidase. Scand J Clin Lab Invest Suppl 1993; 215: 61-74 [PMID: 8327852 DOI: 10.3109/00365519309090698]
51. Ojala PJ, Hirvonen TE, Hermansson M, Somerharju P, Parkkinen J. Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J Leukoc Biol 2007; 82: 1501-1509 [PMID: 17884992 DOI: 10.1189/jlb.0507292]
52. Furuya H, Shimizu Y, Kawamori T. Sphingolipids in cancer. Cancer Metastasis Rev 2011; 30: 567-576 [PMID: 22005951 DOI: 10.1007/s10555-011-9304-1]
53. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, Liu L, Chen T, Li J, Tu H, He X. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int 2012; 32: 331-338 [PMID: 22098666 DOI: 10.1111/j.1478-3231.2011.02666.x]
54. Yang L, Yue S, Yang L, Liu X, Han Z, Zhang Y, Li L. Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J Hepatol 2013; 59: 114-123 [PMID: 23466305 DOI: 10.1016/j.jhep.2013.02.021]
55. El-Mir MY, Badia MD, Luengo N, Monte MJ, Marin JJ. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clin Sci (Lond) 2001; 100: 499-508 [PMID: 11294690 DOI: 10.1042/CS20000199]
56. El-Houseini ME, Amer MA, El-Din AS, El-Sherbiny M, Hussein TD, Mansour O. Evaluation of Serum Total Bile Acids in the Diagnosis of Hepatocellular Carcinoma. Cancer Inst 2000; 12: 307-313
57. Thompson J, Zhang J, Vanden Heuvel J. Activation of farnesoid-X-receptor (FXR) by bioactive lipids. Available from: URL: http://indigobiosciences.com/wp-content/uploads/2014/03/fxrposterv2. pdf
58. Fujino T, Takeuchi A, Maruko-Ohtake A, Ohtake Y, Satoh J, Kobayashi T, Tanaka T, Ito H, Sakamaki R, Kashimura R, Ando K, Nishimaki-Mogami T, Ohkubo Y, Kitamura N, Sato R, Kikugawa K, Hayakawa M. Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation. J Biochem 2012; 152: 577-586 [PMID: 22969091 DOI: 10.1093/jb/mvs101]
59. Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T. Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma. Hepatol Res 2013; 43: 959-969 [PMID: 23369163 DOI: 10.1111/hepr.12047]
60. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011; 9: 171 [PMID: 21985599 DOI: 10.1186/1479-5876-9-171]
61. Suzuki Y, Imai K, Takai K, Hanai T, Hayashi H, Naiki T, Nishigaki Y, Tomita E, Shimizu M, Moriwaki H. Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. J Cancer Res Clin Oncol 2013; 139: 845-852 [PMID: 23411687 DOI: 10.1007/s00432-013-1389-1]
62. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-8930 [PMID: 16982728 DOI: 10.1158/0008-5472.CAN-06-1501]
63. Luo J. Cancer's sweet tooth for serine. Breast Cancer Res 2011; 13: 317 [PMID: 22189202 DOI: 10.1186/bcr2932]
64. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011; 43: 869-874 [PMID: 21804546 DOI: 10.1038/ng.890]
65. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, Yuan B, Garraway LA, Root DE, Mino-Kenudson M, Brachtel EF, Driggers EM, Sabatini DM. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-350 [PMID: 21760589 DOI: 10.1038/nature10350]
66. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012; 336: 1040-1044 [PMID: 22628656 DOI: 10.1126/science.1218595]
67. Kim Y, Lin Q, Glazer PM, Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 2009; 9: 425-434 [PMID: 19519400 DOI: 10.2174/156652409788167113]
68. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O'Reilly M, Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012; 491: 458-462 [PMID: 23064226 DOI: 10.1038/nature11540]
69. Hannelien V, Karel G, Jo VD, Sofie S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 2012; 1825: 117-129
70. Kong J, Kong L, Kong J, Ke S, Gao J, Ding X, Zheng L, Sun H, Sun W. After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma. J Transl Med 2012; 10: 230 [PMID: 23171368 DOI: 10.1186/1479-5876-10-230]
71. Bechara C, Chai H, Lin PH, Yao Q, Chen C. Growth related oncogene-alpha (GRO-alpha): roles in atherosclerosis, angiogenesis and other inflammatory conditions. Med Sci Monit 2007; 13: RA87-RA90 [PMID: 17534244]
72. Smith DF, Galkina E, Ley K, Huo Y. GRO family chemokines are specialized for monocyte arrest from flow. Am J Physiol Heart Circ Physiol 2005; 289: H1976-H1984 [PMID: 15937099 DOI: 10.1152/ajpheart.00153.2005]
73. Zhao XL, Sun T, Che N, Sun D, Zhao N, Dong XY, Gu Q, Yao Z, Sun BC. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. J Cell Mol Med 2011; 15: 691-700 [PMID: 20219012 DOI: 10.1111/j.1582-4934.2010.01052.x]
74. Ebert MP, Lamer S, Meuer J, Malfertheiner P, Reymond M, Buschmann T, Röcken C, Seibert V. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res 2005; 4: 586-590 [PMID: 15822938 DOI: 10.1021/pr049771i]
75. Szutowicz A, Tomaszewicz M, Bielarczyk H. Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Acta Neurobiol Exp (Wars) 1996; 56: 323-339 [PMID: 8787193]
76. Kreis R, Farrow N, Ross BD. Localized 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols. NMR Biomed 1991; 4: 109-116 [PMID: 1650239 DOI: 10.1002/nbm.1940040214]
77. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3 [PMID: 19017551 DOI: 10.1016/j.jhep. 2008.10.014]